US Patent

US9962376 — Methods and ophthalmic devices used in the treatment of ocular allergies

Formulation · Assigned to Johnson and Johnson Vision Care Inc · Expires 2030-06-27 · 4y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent discloses methods and ophthalmic devices for treating allergic conjunctivitis.

USPTO Abstract

Ophthalmic devices and methods of treating allergic conjunctivitis are disclosed herein.

Drugs covered by this patent

ketotifen-fumarate (KETOTIFEN FUMARATE)

Patent Metadata

Patent number: US9962376
Jurisdiction: US
Classification: Formulation
Expires: 2030-06-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Johnson and Johnson Vision Care Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.